Cargando…

Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics

In the present study, we compared the dynamics and composition of microtubules in cell lines derived from the human breast adenocarcinoma MCF-7 containing either the wild-type p53 (wt-p53; MN1) or a dominant-negative variant of p53 gene (mut-p53; MDD2). Mut-p53 cells were significantly resistant to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galmarini, C M, Kamath, K, Vanier-Viornery, A, Hervieu, V, Peiller, E, Falette, N, Puisieux, A, Ann Jordan, M, Dumontet, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377136/ https://www.ncbi.nlm.nih.gov/pubmed/12771997 http://dx.doi.org/10.1038/sj.bjc.6600960

Ejemplares similares

Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity
por: Galmarini, C M, et al.
Publicado: (2001)

Paclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype
por: Bouchet, B P, et al.
Publicado: (2007)

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance
por: Leung, E L, et al.
Publicado: (2008)

Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2
por: Fedier, A, et al.
Publicado: (2002)

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
por: Giovannetti, E, et al.
Publicado: (2007)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

p53 mutation, deprivation and poor prognosis in primary breast cancer
por: Baker, L, et al.
Publicado: (2010)

Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
por: Stengel, C, et al.
Publicado: (2010)

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells
por: Serova, M, et al.
Publicado: (2007)

O(6)-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents
por: Walter, T, et al.
Publicado: (2015)

The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo
por: Akashi, Y, et al.
Publicado: (2007)

Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine
por: Dudley, A C, et al.
Publicado: (2008)

Micronuclei to detect in vivo chemotherapy damage in a p53 mutated solid tumour
por: Driessens, G, et al.
Publicado: (2003)

Alternative iliofemoral revascularization in extensive aortoiliac occlusive disease
por: Giusti, Júlio César Gomes, et al.
Publicado: (2019)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells
por: Maginn, E N, et al.
Publicado: (2011)

Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut
por: Bach, S P, et al.
Publicado: (2006)

p28, A first in class peptide inhibitor of cop1 binding to p53
por: Yamada, T, et al.
Publicado: (2013)

Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation
por: Hostanska, K, et al.
Publicado: (2003)

Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients
por: Faivre, C, et al.
Publicado: (2017)

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers
por: Newman, S P, et al.
Publicado: (2007)

N-(4-iodophenyl)-N′-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice
por: Borel, M, et al.
Publicado: (2007)

Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo
por: Hristodorov, D, et al.
Publicado: (2013)

MG53 Does Not Manifest the Development of Diabetes in db/db Mice
por: Wang, Qiang, et al.
Publicado: (2020)

TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy
por: Lee, S Y, et al.
Publicado: (2010)

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
por: Chen, L, et al.
Publicado: (2014)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53
por: Sorriento, D, et al.
Publicado: (2015)

Doxorubicin and vinorelbine act independently via p53 expression and p38 activation respectively in breast cancer cell lines
por: Liem, A A, et al.
Publicado: (2003)

p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection
por: Lee, E J, et al.
Publicado: (2003)

Potential role of p53 on metallothionein induction in human epithelial breast cancer cells
por: Fan, L Z, et al.
Publicado: (2002)

A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin
por: Tang, H-J, et al.
Publicado: (2004)

Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa
por: de Bruijn, M T, et al.
Publicado: (2010)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Altered TUBB3 expression contributes to the epothilone response of mitotic cells
por: Narvi, E, et al.
Publicado: (2013)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis
por: Duda, D G, et al.
Publicado: (2002)

Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells
por: Zhang, S, et al.
Publicado: (2004)

Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients
por: Mracek, T, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ilb8vvlaetd1p4ctj8kj9sb1ku